BMI Revises Growth Forecast

BMI View: The key drawback to investment in Estonia's drug market is its small size and moderate-to-weak outlook for growth. However, compared to its Baltic peers, Estonia's drug market expenditure per capita was relatively high in 2010 at US$226, compared with Latvia's US$223 and Lithuania's US$183. The market is projected to achieve higher growth rates than Lithuania, but lower than Latvia over the next five years.

To read the full article, please choose one of the following options: